title: A novel celecoxib derivative, OSU03012, induces cytotoxicity in primary CLL cells and transformed B-cell lymphoma cell line via a caspase- and Bcl-2-independent mechanism.
authors.affiliation: Division of Hematology and Oncology, Department of Internal Medicine, The Ohio State University, 320 W 10th Ave, Columbus, OH 43210, USA.
authors.forename: Amy J
authors.initials: AJ
authors.lastname: Johnson
authors.forename: Lisa L
authors.initials: LL
authors.lastname: Smith
authors.forename: Jiuxiang
authors.initials: J
authors.lastname: Zhu
authors.forename: Nyla A
authors.initials: NA
authors.lastname: Heerema
authors.forename: Sara
authors.initials: S
authors.lastname: Jefferson
authors.forename: Andrew
authors.initials: A
authors.lastname: Mone
authors.forename: Michael
authors.initials: M
authors.lastname: Grever
authors.forename: Ching-Shih
authors.initials: CS
authors.lastname: Chen
authors.forename: John C
authors.initials: JC
authors.lastname: Byrd
mesh_terms: D017209:Apoptosis / Q000187:drug effects*; D020169:Caspases / Q000378:metabolism; D002471:Cell Transformation, Neoplastic / Q000378:metabolism*; D004305:Dose-Response Relationship, Drug; D004353:Drug Evaluation, Preclinical; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy / Q000378:metabolism*; D016393:Lymphoma, B-Cell / Q000188:drug therapy / Q000378:metabolism*; D008928:Mitochondria / Q000378:metabolism; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000378:metabolism; D011720:Pyrazoles / Q000494:pharmacology* / Q000627:therapeutic use; D013449:Sulfonamides / Q000494:pharmacology* / Q000627:therapeutic use; D014407:Tumor Cells, Cultured
chemical_list: C500894:OSU 03012; D019253:Proto-Oncogene Proteins c-bcl-2; D011720:Pyrazoles; D013449:Sulfonamides; D020169:Caspases